Abstract 2420: Evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker utilizing a tissue-free epigenomic assay in early-stage triple negative breast cancer (TNBC)
Randomized trial evaluates ctDNA monitoring for recurrence in early-stage triple negative breast cancer, suggesting clinical utility.
Key Points
Detection of circulating tumor DNA was achieved with 75% sensitivity in the patient cohort, indicating strong prognostic value for early detection of recurrence.
Among node-positive cancers, ctDNA was detected at 100%, significantly higher than the 58% detection in node-negative cases, highlighting its relevance in progression risk.
Assessment using a tissue-free epigenomic assay effectively screened for ctDNA across multiple time points following neoadjuvant chemotherapy and surgery for accurate monitoring of recurrence risk in patients evaluated over 5 years in a clinical trial context. Prior to recurrence, ctDNA presence correlated with a median lead time of 5 months, underscoring its potential role in patient management.